性,年龄,身体组成和功能对自我报告的酒精消费和酸乙醇之间的关系的影响 - 来自HUNT研究的数据
Ragnhild Bergene Skråstad1,2, Øyvind Salvesen3, Trine Naalsund Andreassen1
1Department of Clinical Pharmacology, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway.
Basic & clinical pharmacology & toxicology
|December 2, 2025
概括
性别和身体构成显著影响从酸丁乙醇 (PEth) 水平获得的酒精消费估计. 男性和软肌肉质量较高的人可能会在相同的PEth度下消耗更多的酒精.
科学领域:
- 酒精消费的生物标志物 饮酒的生物标志物
- 药理动力学 药理动力学
- 人口健康研究 人口健康研究
背景情况:
- 酸乙醇 16:0/18:1 (PEth) 是饮酒的关键生物标志物.
- 影响PEth剂量-反应关系的因素,如性别和身体组成,需要进一步调查.
研究的目的:
- 为了确定性别,年龄,体型,身体组成和功能是否影响基于PEth水平的酒精消费估计.
- 分析这些生理因素对PEth作为酒精生物标志物的准确性的影响.
主要方法:
- 一项基于人口的纵向队列研究 (Trøndelag健康研究,HUNT4) 涉及24,902名参与者.
- 使用回归建模来评估生理因素和PEth度之间的关联.
主要成果:
- 性和软瘦质量被确定为在给定的PEth度下酒精消费的显著独立预测因素.
- 男性的酒精消耗量比女性多21%,柔软瘦体量增加10%与相当于PEth水平的酒精消耗量增加3.9%相关.
- 当软瘦质量被排除在模型之外时,身高和体重成为重要的预测因素.
结论:
- 性别,身体组成和体型影响酒精摄入量和PEth度之间的剂量反应关系.
- 这些因素在估计PEth测量的乙醇消耗时带来了不确定性,突出了对个性化解释的需求.
相关概念视频
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
216
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
216
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
221
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
221
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
161
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
161
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
183
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
183


